Abstract
Visual prostheses aim at restoring useful vision to patients who have become blind. This useful vision should enable them to regain autonomy in society for navigation, face recognition or reading. Two retinal prostheses have already obtained market authorization for patients affected by retinal dystrophies while a new device is in clinical trials for patients affected by age-related macular degeneration. Various prostheses, in particular cortical prostheses, are currently in clinical trials for optic neuropathies (glaucoma). Optogenetic therapy, an alternative strategy, has now reached the stage of clinical trials at the retinal level while moving forward at the cortical level. Other innovating strategies have obtained proofs of concepts in rodents but require a further validation in large animals prior to their evaluation on patients. Restoring vision should therefore become a reality for many patients even if this vision will not be as extensive and perfect as natural vision.
Highlights
Visual prostheses aim at restoring useful vision to patients who have become blind
Two retinal prostheses have already obtained market authorization for patients affected by retinal dystrophies while a new device is in clinical trials for patients affected by age-related macular degeneration
Restoring vision should become a reality for many patients even if this vision will not be as extensive and perfect as natural vision. ‡
Summary
Antenne RF par radiofréquence (RF) au dispositif implanté. Ce dispositif implanté est attaché autour de l’œil par une sangle qui contient l’antenne RF. La puce électronique contenue dans le boitier génère des courants électriques qui se propagent via le câble vers les 60 électrodes de l’implant. Notez la perte de résolution sur l’image d’un visage lors de la stimulation avec 60 électrodes même dans le cas favorable où chaque électrode produit un pixel de l’image perçue
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have